Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Sograzepide is an effective and highly selective Gastrin/CCK-B antagonist (IC50: 0.1 nM), has an inhibitory effect on Gastrin/CCK-A activity (IC50: 502 nM). Sograzepide replaces the specific binding of [125I]CCK-8 to the rat brain, cloned canine, and cloned human Gastrin/CCK-B receptors (Ki: 0.068, 0.62 and 0.19 nM, respectively).
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 1,980 | 6-8周 | ||
25 mg | ¥ 8,930 | 6-8周 | ||
50 mg | ¥ 11,600 | 6-8周 | ||
100 mg | ¥ 17,500 | 6-8周 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,280 | 6-8周 |
产品描述 | Sograzepide is an effective and highly selective Gastrin/CCK-B antagonist (IC50: 0.1 nM), has an inhibitory effect on Gastrin/CCK-A activity (IC50: 502 nM). Sograzepide replaces the specific binding of [125I]CCK-8 to the rat brain, cloned canine, and cloned human Gastrin/CCK-B receptors (Ki: 0.068, 0.62 and 0.19 nM, respectively). |
靶点活性 | Gastrin/CCK-A:501 nM, Gastrin/CCK-B:0.1 nM |
体内活性 | Sograzepide (0.1 μmol/kg; intravenous injection) has an inhibition effect on pentagastrin-induced gastric acid secretion in anesthetized rats (ED50: 87?nmol/kg). Sograzepide (intravenous injection; 10 μM/kg) inhibits pentagastrin-induced acid secretion (ED50: 0.0086 μM/kg). Sograzepide (intravenous injection; p.o.) in Heidenhain pouch dogs, inhibits pentagastrin-stimulated gastric acid secretion in a dose-dependent manner (ED50: 0.018 and 0.020 μM/kg, respectively) [1][2]. |
别名 | YM-220, Netazepide, YF 476 |
分子量 | 498.58 |
分子式 | C28H30N6O3 |
CAS No. | 155488-25-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (200.57 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.0057 mL | 10.0285 mL | 20.057 mL | 50.1424 mL |
5 mM | 0.4011 mL | 2.0057 mL | 4.0114 mL | 10.0285 mL | |
10 mM | 0.2006 mL | 1.0028 mL | 2.0057 mL | 5.0142 mL | |
20 mM | 0.1003 mL | 0.5014 mL | 1.0028 mL | 2.5071 mL | |
50 mM | 0.0401 mL | 0.2006 mL | 0.4011 mL | 1.0028 mL | |
100 mM | 0.0201 mL | 0.1003 mL | 0.2006 mL | 0.5014 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Sograzepide 155488-25-8 Others YM 220 YM-220 Netazepide YF 476 YF476 YM220 YF-476 Inhibitor inhibitor inhibit